UY39295A - ANTICUERPOS DE FIJACIÓN A PROTOFIBRILLAS DE a-SINUCLEÍNA - Google Patents

ANTICUERPOS DE FIJACIÓN A PROTOFIBRILLAS DE a-SINUCLEÍNA

Info

Publication number
UY39295A
UY39295A UY0001039295A UY39295A UY39295A UY 39295 A UY39295 A UY 39295A UY 0001039295 A UY0001039295 A UY 0001039295A UY 39295 A UY39295 A UY 39295A UY 39295 A UY39295 A UY 39295A
Authority
UY
Uruguay
Prior art keywords
synuclein
protofibrille
binding antibodies
ban0805
antibodies
Prior art date
Application number
UY0001039295A
Other languages
English (en)
Inventor
Norström Eva
Jessica Sigvardson
Patrik Nygren
Original Assignee
Bioarctic Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioarctic Ab filed Critical Bioarctic Ab
Publication of UY39295A publication Critical patent/UY39295A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente divulgación se basa, en parte, en el descubrimiento de anticuerpos que se dirigen selectivamente a agregados de a-sinucleína humana tales como oligómeros/protofibrillas, tales como BAN0805. BAN0805 tiene una menor tendencia a fijarse a la diana de a-sinucleína monomérica no deseada en comparación con el anticuerpo monoclonal de ratón mAb47.
UY0001039295A 2020-06-26 2021-06-25 ANTICUERPOS DE FIJACIÓN A PROTOFIBRILLAS DE a-SINUCLEÍNA UY39295A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063044881P 2020-06-26 2020-06-26
US202063071150P 2020-08-27 2020-08-27

Publications (1)

Publication Number Publication Date
UY39295A true UY39295A (es) 2022-01-31

Family

ID=77627146

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039295A UY39295A (es) 2020-06-26 2021-06-25 ANTICUERPOS DE FIJACIÓN A PROTOFIBRILLAS DE a-SINUCLEÍNA

Country Status (13)

Country Link
US (2) US11339212B2 (es)
EP (1) EP4172199A1 (es)
JP (2) JP7337959B2 (es)
KR (1) KR20230027095A (es)
CN (1) CN115803341A (es)
AU (1) AU2021298222A1 (es)
CA (1) CA3181207A1 (es)
IL (1) IL298584B1 (es)
MX (1) MX2022016005A (es)
TW (1) TW202212357A (es)
UY (1) UY39295A (es)
WO (1) WO2021260434A1 (es)
ZA (1) ZA202211843B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL298584B1 (en) 2020-06-26 2024-06-01 Bioarctic Ab Antibodies against protofibril-binding alpha-synuclein

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9911291A (pt) 1998-07-03 2001-12-04 Innogenetics Nv Diagnóstico diferencial de neurodegeneração
WO2002003911A2 (en) 2000-07-07 2002-01-17 Lars Lannfelt Prevention and treatment of alzheimer's disease
US20060018918A1 (en) 2000-12-27 2006-01-26 Board Of Regents, The University Of Texas System Production of stabilized conformational isomers of disease associated proteins
US20080014194A1 (en) 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
US7674599B2 (en) 2003-11-08 2010-03-09 Elan Pharmaceuticals, Inc. Methods of using antibodies to detect alpha-synuclein in fluid samples
US20050203010A1 (en) 2003-11-14 2005-09-15 Atgen Co., Ltd. Novel peptides conferring environmental stress resistance and fusion proteins including said peptides
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
WO2007089862A2 (en) 2006-01-31 2007-08-09 Elan Pharmaceuticals, Inc. Alpha-synuclein kinase
NZ567888A (en) 2006-03-23 2010-08-27 Bioarctic Neuroscience Ab Improved protofibril selective antibodies and the use thereof
EP2282758B1 (en) * 2008-04-29 2018-11-21 BioArctic AB Antibodies and vaccines for use in therapeutic and diagnostic methods for alpha-synuclein-related disorders
MX2011006422A (es) 2008-12-19 2011-09-15 Panima Pharmaceuticals Ag Autoanticuerpos humanos anti-alfa-sinucleina.
PT2448968T (pt) 2009-06-29 2021-04-30 Bioarctic Ab ANTICORPOS SELETIVOS PARA PROTOFIBRILAS/OLIGÓMEROS DE ß- AMILOIDE TRUNCADA EM N-TERMINAL
SI2539366T1 (en) 2010-02-26 2018-05-31 Bioarctic Neuroscience Ab PROTOTRIBRIL-RELATED APPEALS AND THEIR USE IN THERAPEUTIC AND DIAGNOSTIC METHODS FOR PARKINSON'S DISEASE, DEMONS WITH LEWY BODIES AND OTHER ALPHA-SYNUKLEINOPATHIES
UY33578A (es) * 2010-08-31 2012-03-30 Sanofi Sa PÉPTIDO O COMPLEJO PEPTÍDICO QUE SE UNE A INTEGRINA a(ALFA) Y MÉTODOS Y USOS QUE IMPLICAN A LOS MISMOS
HUE041391T2 (hu) 2011-06-23 2019-05-28 Biogen Int Neuroscience Gmbh Anti-alfa-szinukleinkötõ molekulák
US9534044B2 (en) 2013-02-28 2017-01-03 United Arab Emirates University Alpha-synuclein antibodies and uses thereof
EP3712174B1 (en) * 2013-12-24 2022-03-16 Janssen Pharmaceutica NV Anti-vista antibodies and fragments
US11773166B2 (en) * 2014-11-04 2023-10-03 Ichnos Sciences SA CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
US20190330335A1 (en) * 2015-10-06 2019-10-31 Alector Llc Anti-trem2 antibodies and methods of use thereof
IL298584B1 (en) 2020-06-26 2024-06-01 Bioarctic Ab Antibodies against protofibril-binding alpha-synuclein

Also Published As

Publication number Publication date
US11339212B2 (en) 2022-05-24
CN115803341A (zh) 2023-03-14
JP2023159299A (ja) 2023-10-31
ZA202211843B (en) 2024-02-28
JP7337959B2 (ja) 2023-09-04
IL298584A (en) 2023-01-01
KR20230027095A (ko) 2023-02-27
WO2021260434A1 (en) 2021-12-30
CA3181207A1 (en) 2021-12-30
JP2023525174A (ja) 2023-06-15
EP4172199A1 (en) 2023-05-03
IL298584B1 (en) 2024-06-01
AU2021298222A1 (en) 2022-12-15
MX2022016005A (es) 2023-02-02
US20230080536A1 (en) 2023-03-16
TW202212357A (zh) 2022-04-01
US20210403542A1 (en) 2021-12-30

Similar Documents

Publication Publication Date Title
CY1124691T1 (el) Διειδικα αντισωματα ειδικα για pd1 και τιμ3
EA202092847A1 (ru) Антитела к cd3 и их применение
AR101846A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
CR20200171A (es) Contorsbodies 2 + 1 biespecíficos
EA202190542A1 (ru) Сконструированные биспецифические белки
CO2019011458A2 (es) Anticuerpo monoclonal para pd-l1
EA201990894A9 (ru) Анти-pd-1/анти-her2 гетеродимерное биспецифическое антитело со структурой природного антитела и способ его получения
EA201990673A1 (ru) Антитела, специфически связывающиеся с il-17a, и их функциональные фрагменты
NZ631098A (en) Anti-hepcidin antibodies and uses thereof
FI3402821T3 (fi) PSMA-sitova vasta-aine ja sen käyttöjä
EA201070539A1 (ru) НОВЫЕ АНТИТЕЛА, СПЕЦИФИЧНЫЕ К β-АМИЛОИДНЫМ ПЕПТИДАМ, И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ДИАГНОСТИЧЕСКИХ ИЛИ ЛЕКАРСТВЕННЫХ СРЕДСТВ
PE20230381A1 (es) Proteina de union a rgma
MX2020010094A (es) Kir3dl3 como receptor de hhla2, anticuerpos anti-hhla2 y usos de estos.
CL2021002792A1 (es) Anticuerpo monoclonal que se une específicamente a gitr
CU20200105A7 (es) Anticuerpos que se unen a la proteína de envoltura del virus zika
PE20181199A1 (es) Anticuerpos que se unen al receptor cannabinoide 1 (cb1) humano
EA201991464A1 (ru) АНТИТЕЛО К α-СИНУКЛЕИНУ И ЕГО ПРИМЕНЕНИЕ
MX2020013606A (es) Constructos de anticuerpos multiespecificos.
MX2020003193A (es) Anticuerpos recombinantes mono- o biespecificos multivalentes para fines analiticos.
UY39295A (es) ANTICUERPOS DE FIJACIÓN A PROTOFIBRILLAS DE a-SINUCLEÍNA
EA201992316A1 (ru) Композиции и способы для диагностики рака предстательной железы
DOP2022000129A (es) Anticuerpos contra la integrina alfa 11 beta 1
MD3365367T2 (ro) Anticorpi monoclonali împotriva ploşniţelor de pat și procedee de obţinere și utilizare a acestora
AR122752A1 (es) ANTICUERPOS DE FIJACIÓN A PROTOFIBRILLAS DE a-SINUCLEÍNA
WO2018231339A3 (en) TYROSINE PHOSPHORYLATED ANTI-PD-1 ANTIBODIES AND USES THEREOF